3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
CNS
1
Conditions
Multiple Myeloma
81
Neoplasms, Plasma Cell
27
Neoplasms
13
Brain Neoplasms
11
Prostatic Neoplasms
10
Central Nervous System Neoplasms
10
Melanoma
9
Leukemia
9
Glioblastoma
8
Gliosarcoma
7
Glioma
7
Leukemia, Lymphocytic, Chronic, B-Cell
6
Carcinoma, Hepatocellular
6
Recurrence
5
Myeloproliferative Disorders
5
Myelodysplastic Syndromes
5
Lymphoma, Mantle-Cell
5
Lung Neoplasms
5
Waldenstrom Macroglobulinemia
4
Sarcoma
4
Myelodysplastic-Myeloproliferative Diseases
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
4
Immunoglobulin Light-chain Amyloidosis
4
Carcinoma, Renal Cell
4
Uveal Melanoma
3
Oligodendroglioma
3
Neuroblastoma
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Follicular
3
Interventions
Irinotecan
13
Cyclophosphamide
11
Vincristine
10
Filgrastim
10
Radiotherapy
9
Ifosfamide
9
Doxorubicin
9
Dactinomycin
7
Melphalan
6
Granulocyte Colony-Stimulating Factor
6
Etoposide
6
cixutumumab
5
Sirolimus
5
Peripheral Blood Stem Cell Transplantation
5
pegfilgrastim
4
Topotecan
4
Temozolomide
4
Radiation
4
Gemcitabine
4
Busulfan
4
temsirolimus
3
sargramostim
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
trioctyl phosphine oxide
2
regorafenib
2
olaparib
2
etoposide phosphate
2
eribulin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Rhabdomyosarcoma
×
Thalidomide
×
Clear all
NCT01661400
2024-01-31
ASCR
Washington University School of Medicine
Phase 1
Completed
14 enrolled